AEB071 + MEK162
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Aug 1, 2013 → May 1, 2015
NCT ID
NCT01801358About AEB071 + MEK162
AEB071 + MEK162 is a phase 1/2 stage product being developed by Pfizer for Uveal Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01801358. Target conditions include Uveal Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Uveal Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01801358 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Uveal Melanoma